Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27774 | 0.82 | MAPT (1.00) | MAPTALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL6476736 | 0.82 | MAPT (0.58) | MAPTALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL14809723 | 0.81 | NPSR1 (0.46) | MAPTALDH1A1LMNAHTTPOLB | |
| SCHEMBL22209996 | 0.81 | NPSR1 (0.46) | MAPTALDH1A1LMNAHTTPOLB | |
| SCHEMBL22194704 | 0.81 | NPSR1 (0.46) | MAPTALDH1A1LMNAHTTPOLB | |
| SCHEMBL2171315 | 0.80 | MAPT (0.49) | MAPTALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL6491940 | 0.80 | MAPT (0.48) | MAPTALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL9969608 | 0.79 | MAPT (0.55) | MAPTALDH1A1SMN1; SMN2LMNAPOLB | |
| SCHEMBL31437975 | 0.79 | MAPT (0.62) | MAPTALDH1A1SMN1; SMN2LMNARXFP1 | |
| SCHEMBL17888540 | 0.79 | MAPT (0.79) | MAPTALDH1A1SMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-03-08 | — | — | US | disclosed |
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2015-06-11 | — | — | US | disclosed |
| US-8841263-B2 | Macrocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8202843-B2 | Macrocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CCNO, PTGDR, CCNE1 | MAPT 4552/4885ALDH1A1 2970/4885SMN1; SMN2 2993/4885 |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | VIP, PROKR1, PGC | MAPT 4336/4885ALDH1A1 3986/4885SMN1; SMN2 3139/4885 |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | CCNO, PTGDR, CCNE1 | MAPT 4552/4885ALDH1A1 2970/4885SMN1; SMN2 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.